RESUMO
BACKGROUND:Intra-articular injection of sodium hyaluronate is an effective method for the treatment of knee osteoarthritis, with significant effect and less adverse reactions, but the mechanism is unclear. OBJECTIVE:Through testing the malondialdehyde and superoxide dismutase levels in the synovial fluid of knee osteoarthritis before and after injection of sodium hyaluronate, to evaluate the clinical efficacy of sodium hyaluronate in the treatment of knee osteoarthritis. METHODS:Thirty-seven patients with knee osteoarthritis (40 knees) were enroled and divided into mild (n=10, 10 knees), moderate (n=17, 18 knees), and severe (n=10, 12 knees) groups according to the Japan's knee osteoarthritis indications. Patients were subjected to intra-articular injection of 25 mg sodium hyaluronate, once a week for 5 weeks. The levels of malondialdehyde and superoxide dismutase in the synovial fluid before and 4 weeks after treatment were detected, and then clinical effects were evaluated based on the clinical scores according to the Japan’s knee osteoarthritis indications. RESULTS AND CONCLUSION: The indication rating results of the mild and moderate groups were decreased significantly 4 weeks after injection (P < 0.05), but there were no significant difference in the severe group before and after treatment. The malondialdehyde level in the synovial fluid was decreased obviously in the three groups at 4 weeks after injection (P < 0.05), while the level of superoxide dismutase was increased remarkably (P < 0.05). These findings indicate that sodium hyaluronate can treat knee osteoarthritis by reducing the malondialdehyde level and increasing superoxide dismutase level in the synovial fluid, but this method is more suitable for treatment of mild to moderate knee osteoarthritis.
RESUMO
AIM: To investigate the feasibility and its mechanisms of improving therapeutic effect by antisense gene therapy combined with chemotherapy in osteosarcoma. METHODS: The human osteosarcoma implanted tumor model in the nude mice was established. By intratumoral injection and abdominal cavity administration, the tumor bearing mice were treated with survivin ASODN in combination with diamminedichloroplatinum (DDP) for a week. Comparison with each single - agent therapy and control group was performed in aspects such as tumor growth condition, pathological changes of tumor tissues; survivin protein expression in tumor tissues by immunohistochemistry, survivin mRNA expression levels by RT -PCR method and tumor apoptosis by Tdt -mediated dUTP nick end labeling (TUNEL). RESULTS: All nude mice survived the therapy. As compared with the control group, the antisense gene therapy group presented synchronous decrease in survivin mRNA and protein expression; all therapy group displayed tumor growth inhibition and cell apoptosis with different extent; while in contrast to single - agent therapy group, the combined therapy group showed stronger inhibition of tumor growth and abundant tumor cell apoptosis with the highest apoptotic rate. CONCLUSION: Synergistic effect was achieved by combination of DDP with ASODN that may overcome drug resistant of DDP and the combined strategy may shed new light on the cancer therapy.
RESUMO
AIM: Osteosarcoma OS-732 cell line was used to investigate the effect of antisense oligonucleotide (ASODN) on survivin expression and its inducible effect on tumor cells apoptosis. METHODS: ASODN of specific target survivin was designed, synthesized and then transfer to OS-732 cell line with different concentrations and time points. At the same time blank control group, sense oligonucleotide (SOND) group were set up for comparison. Reverse tanscriptionase-polymerase chain reaction (RT-PCR), Western blotting and immunohistochemistry were used to detect the expressions of survivin mRNA and protein in each OS-732 cell line group. Acridine orange /ethidium bromide (AO/EB) staining and flow cytometry were used to detect the apoptosis level and morphologic change. Mononuclear cell direct cytotoxicity assay (MTT) was used to estimate cell growth suppression. Kinase activity assay method was used to estimate the activity of caspase-3 in the cells. RESULTS: Compared with control group and SOND group, in ASODN groups, the expression of survivin mRNA and protein were obviously weaken, apoptosis rate and caspase-3 activity apparently increased, cells growth was inhibited. In each ASODN group, the effect above-mentioned has time- and concentration-dependent manner. There was no obviously difference of each index in each SODN and blank control groups. CONCLUSION: ASODN down-regulated the expression of survivin gene in OS-732 cell line specifically, and activated apoptosis effectively. It plays an important role in inducing tumor apoptosis and suppressing cell proliferation.
RESUMO
Objective To investigate the expression of survivin (an apoptosis inhibitor) in thyroid carcinoma and its relationship with vascular endothelial growth factor (VEGF) expression. Methods Sixty-eight cases of thyroid carcinoma, 12 cases of thyroid adenoma and 10 cases of normal thyroid tissue were involved. Immunohistochemistry (SABC method) was used to detect the expression of survivin, caspase-3 and VEGF, and then their relationship with the major clinicalpathologicalparametersofthyroidcarcinoma was analysed. Results No survivin was expressedinnormalthyroidtissue,butsurvivinwasweakly expressed in thyroid adenoma (16.7%) and strongly expressed in thyroid carcinoma (57.4%); caspase-3 was obviously expressed in three kinds of tissue (70.0%, 75.0%, 69.1%), and VEGF was expressed in 75.0% of thyroid carcinoma and 41.7% of thyroid adenoma. In thyroid carcinoma, survivin expression had no correlation with caspase-3 expression, but significant positive correlation existed between surviving and VEGF (r=0.302,P